Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needsAI-driven ...
Eli Lilly and Co (NYSE:LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage ...
AI Foundation Models to Enable Precision ADC Clinical Development and Response Intelligence BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic ...
AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Biotech firms use AI in trials to target patients more ...
OneMedNet Corporation (Nasdaq: ONMD) (the 'OneMedNet,” the 'Company,” 'we,” 'us” or 'our”), a leading provider of regulatory ...
BullFrog AI Holdings Inc. BFRG on Wednesday introduced bfARENAS, a scenario-based decision engine. The engine aims at ...
Click Eligibility™ Reduces Screening Time from Months to Minutes, Accelerating Drug DevelopmentSAN DIEGO--(BUSINESS ...
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the ...
Lilly and NVIDIA (NVDA) launch AI co-innovation lab to tackle drug discovery challenges. NVIDIA collaborates with Thermo Fisher to build autonomous lab infrastructure for scalable scientific discovery ...
The initiative, launched on April 2, 2026, aims to develop end-to-end AI-powered solutions to streamline regulatory workflows, accelerate drug approvals, and enhance access to healthcare innovations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results